Vanadium in the detection, prevention and treatment of cancer: The in vivo evidence

Cancer Letters

Volumn 294, Issue 1, 2010, Pages 1-12

  Bishayee, Anupam ^a   Waghray, Abhijeet ^a   Patel, Mehool A ^b,c   Chatterjee, Malay ^d  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Northeastern Ohio Medical University   (United States)

^c SUMMA HEALTH SYSTEM   (United States)

^d JADAVPUR UNIVERSITY   (India)

Author keywords

Cancer; Chemoprevention; Detection; Therapy; Vanadium

Indexed keywords

AMMONIUM VANADYLTARTRATE; BIS(ETHYLMALTOLATO)OXOVANADIUM; DIAMMONIUM VANADOTARTRATE; ISOTOPE; METVAN; ORTHOVANADIC ACID; PHEOPHORBIDE; SODIUM TETRAVANADIC ACID; UNCLASSIFIED DRUG; VANADATE SODIUM; VANADIUM; VANADIUM 48; VANADIUM ALBUMIN; VANADIUM DERIVATIVE; VANADOCENE DICHLORIDE; VANADYL SULFATE;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABNORMAL FECES; ADRENAL DISEASE; ALBUMINURIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW TOXICITY; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CHOLESTEROL BLOOD LEVEL; COLON ADENOMA; COLON CANCER; COLON CARCINOMA; CONNECTIVE TISSUE TUMOR; DIARRHEA; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EHRLICH ASCITES TUMOR; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LEIOMYOSARCOMA; LIPOPROTEIN BLOOD LEVEL; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TOXICITY; LOW DRUG DOSE; LYMPHATIC LEUKEMIA; LYMPHOSARCOMA; NAUSEA; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; SALIVATION; SHORT SURVEY; SIDE EFFECT; SINGLE DRUG DOSE; TONGUE DISEASE; UREA BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ANIMALIA;

EID: 77953022969     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.01.030     Document Type: Review

References (107)

1. Almedeida M., Filipe S., Hunianes M., Mala M.F., Melo R., Severino N., Silva J.A., Frueesto da Silva J.J., Wever R. Vanadium haloperoxidases from brown algae of the Laminariaceae family. Phytochemistry 2001, 57:633-642.
2. Sakurai H., Katoh A., Yoshikawa Y. Chemistry and biochemistry of insulin-mimetic vanadium and zinc complexes: trial for treatment of diabetes mellitus. Bull. Chem. Soc. Jpn. 2006, 79:1645-1664.
3. Mukherjee B., Patra B., Mahapatra S., Banerjee P., Tewari A., Chatterjee M. Vanadium - an element of atypical biological significance. Toxicol. Lett. 2004, 150:135-143.
4. Barceloux D.G. Vanadium. J. Toxicol. Clin. Toxicol. 1999, 37:265-278.
5. Byrne A.R., Kosta L. Vanadium in foods and in human body fluids and tissues. Sci. Total Environ. 1978, 10:17-30.
6. Badmaev V., Prakash S., Majeed M. Vanadium: a review of its potential role in the fight against diabetes. J. Altern. Complement. Med. 1999, 5:273-291.
7. A. Bishayee, Ph.D. Thesis, Jadavpur University, Calcutta, 1995.
8. Degani H., Gohin M., Karlish S.J.D., Shechter Y. Electron paramagnetic studies and insulin like effects of vanadium in rat adipocytes. Biochemistry 1981, 20:5795-5799.
9. Sabbioni E., Marafante E. Relations between iron and vanadium metabolism: in vivo incorporation of vanadium into iron proteins of the rat. J. Toxicol. Environ. Health 1981, 8:419-429.
10. Fantus I.G., Deragon G., Lai R., Tang S. Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Mol. Cell. Biochem. 1995, 153:103-112.
11. Neckay B.R., Nanninga L.D., Nechay P.S. Vanadyl (IV) and vanadate (V) binding to selected endogenous phosphate, carboxyl and amino ligands; calculations on cellular vanadium species distribution. Arch. Biochem. Biophys. 1986, 251:128-138.
12. Edel J., Sabbioni E. Retention of intratrachealy instilled and ingested tetravalent and pentavalent vanadium in rat. J. Trace Elem. Electrol. Health Dis. 1988, 21:23-30.
13. Domingo J.L., Gomez M., Sanchez D.J., Llobet J.M., Keen C.L. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol. Cell. Biochem. 1995, 153:233-240.
14. Merritt K., Brown S.A. Distribution of titanium and vanadium following repeated injection of high-dose salts. J. Biomed. Mater. Res. 1995, 29:1175-1178.
15. 48V-labeled compounds in rats. J. Appl. Physiol. 1998, 84:569-575.
16. Tsiani E., Fantus I.G. Vanadium compounds: biological actions and potential as pharmacological agents. Trends Endocrinol. Metab. 1997, 8:51-58.
17. Nriagu J.P. Vanadium in the Environment, Part 2: Health Effects 1998, John Wiley and Sons, Inc., New York.
18. French R.J., Jones P.J. Role of vanadium in nutrition: metabolism, essentiality and dietary consideration. Life Sci. 1993, 52:339-346.
19. Stern A., Yin X., Tsang S.S., Davidson A., Moon A.J. Vanadium as a modulator of cellular regulatory cascades and oncogene expression. Biochem. Cell. Biol. 1993, 71:103-112.
20. Dessoize B. Metal and metal compounds in cancer treatment. Anticancer Res. 2004, 24:1529-1544.
21. Kieler J., Gromek A., Nissen N.I. Studies on the antineoplastic effect of vanadium salts. Acta Chir. Scand. 1965, 343:154-164.
22. Evangelou A.M. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 2002, 42:249-265.
23. Ray R.S., Rana B., Swami B., Venu V., Chatterjee M. Vanadium mediated apoptosis and cell cycle arrest in MCF7 cell line. Chem.-Biol. Interact. 2006, 163:239-247.
24. Klein A., Holko P., Ligeza J., Kordowiak A.M. Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145). Folia Biol. 2008, 56:115-121.
25. Kostova I. Titanium and vanadium complexes as anticancer agents. Anticancer Agents Med. Chem. 2009, 9:827-842.
26. Thompson H.J., Chasten N.D., Meeker L.D. Dietary vanadyl (IV) sulfate inhibits chemically-induced mammary carcinogenesis. Carcinogenesis 1984, 5:849-851.
27. Bishayee A., Oinam S., Basu M., Chatterjee M. Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase I and II xenobiotic metabolizing enzymes. Breast Cancer Res. Treat. 2000, 63:133-145.
28. Ray R.S., Roy S., Ghosh S., Kumar M., Chatterjee M. Suppression of cell proliferation, DNA protein cross-links, and induction of apoptosis by vanadium in chemical rat mammary carcinogenesis. Biochim. Biophys. Acta 2004, 1675:165-173.
29. Ray R.S., Basu M., Ghosh B., Smanta K., Chatterjee M. Vanadium, a versatile biochemical effector in chemical rat mammary carcinogenesis. Nutr. Cancer 2005, 51:184-186.
30. Ray R.S., Roy S., Samanta S., Maitra D., Chatterjee M. Protective role of vanadium on the early process of rat mammary carcinogenesis by influencing expression of metallothionein, GGT-positive foci and DNA fragmentation. Cell Biochem. Funct. 2005, 23:447-456.
31. Abdel-Mageed A., Agrawal K.C. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther. 1997, 4:199-207.
32. Jin R., Chow V.T., Tan P.H., Dheen S.T., Duan W., Bay B.H. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002, 23:81-86.
33. Ray R.S., Ghosh B., Rana A., Chatterjee M. Suppression of cell proliferation induction, of apoptosis and cell cycle arrest: chemopreventive activity of vanadium in vivo and in vitro. Int. J. Cancer 2006, 120:13-23.
34. Köpf-Maier P., Wagner W., Hessse B., Köpf H. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect. Eur. J. Cancer 1981, 17:665-669.
35. Köpf-Maier P., Krahl D. Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem.-Biol. Interact. 1983, 44:317-328.
36. Köpf-Maier P., Wagner W., Liss E. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis - diamminedichloroplatinum(II) and metallocene dichlorides. J. Cancer Res. Clin. Oncol. 1981, 201:21-30.
37. Köpf-Maier P. Development of necroses virus, activation and giant cell formation after treatment of Ehrlich ascites tumor with metallocene dichlorides. J. Cancer Res. Clin. Oncol. 1982, 103:145-164.
38. Murthy M.S., Rao L.N. Antitumor and toxicologic properties of the organometallic anticancer agent vanadocene dichloride. Inorg. Chim. Acta 1988, 152:117-124.
39. El-Naggar M.M., El-Waseef A.M., El-Halafawy K.M., El-Sayed I.H. Antitumor activities of vanadium(IV), manganese(IV), iron(III), cobalt(II), and copper(II) complexes of 2-methylaminopyridine. Cancer Lett. 1998, 133:71-76.
40. 2]}. Clin. Cancer Res. 2001, 7:2124-2133.
41. D'Cruz O.J., Uckun F.M. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs 2002, 11:1829-1836.
42. Scrivens P.J., Alaoui-Jamali M.A., Giannini G., Wang T., Loignon M., Batist G., Sandor V.A. Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. Mol. Cancer Ther. 2003, 2:1053-1059.
43. Kingsnorth A.N., LaMuraglia G.M., Ross J.S., Malt R.A. Vanadate supplements and 1,2-dimethylhydrazine induced colon cancer in mice: increased thymidine incorporation without enhanced carcinogenesis. Br. J. Cancer 1986, 53:683-686.
44. Kanna P.S., Mahendrakumar C.B., Chatterjee M., Hemalatha P., Datta S., Chakraborty P. Vanadium inhibits placental glutathione S-transferase (GST-P) positive foci in 1,2-dimethyl hydrazine induced rat colon carcinogenesis. J. Biochem. Mol. Toxicol. 2003, 17:357-365.
45. Kanna P.S., Mahendrakumar C.B., Chakraborty T., Hemalatha P., Banerjee P., Chatterjee M. Effect of vanadium on colonic aberrant crypt foci induced in rats by 1,2-dimethyl hydrazine. World J. Gastroenterol. 2003, 9:1020-1027.
46. Kanna P.S., Mahendrakumar C.B., Indira B.N., Srivastawa S., Kalaiselvi K., Elayaraja T., Chatterjee M. Chemopreventive effects of vanadium toward 1,2-dimethylhydrazine-induced genotoxicity and preneoplastic lesions in rat colon. Environ. Mol. Mutagen. 2004, 44:113-118.
47. Kanna P.S., Saralaya M.G., Samanta K., Chatterjee M. Vanadium inhibits DNA-protein cross-links and ameliorates surface level changes of aberrant crypt foci during 1,2-dimethylhydrazine induced rat colon carcinogenesis. Cell Biol. Toxicol. 2005, 21:41-52.
48. 6-methylguanine DNA adducts, p53 expression, inducible nitric oxide synthase downregulation and apoptotic induction. Mutat. Res. 2008, 650:123-131.
49. 3 combination in inhibitions of 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Biochim. Biophys. Acta 2008, 1780:1106-1114.
50. Bishayee A., Chatterjee M. Selective enhancement of glutathione S-transferase activity in liver and extrahepatic tissues of rat following oral administration of vanadate. Acta Physiol. Pharmacol. Bulg. 1993, 19:83-89.
51. Bishayee A., Chatterjee M. Time course effects of vanadium supplement on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol. Trace Elem. Res. 1995, 48:275-285.
52. Bishayee A., Chatterjee M. Inhibition of altered liver cell foci and persistent nodule growth by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in rats. Anticancer Res. 1995, 15:455-461.
53. Bishayee A., Chatterjee M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. Br. J. Cancer 1995, 71:1214-1220.
54. Bishayee A., Karmakar R., Mandal A., Kundu S.N., Chatterjee M. Vanadium-mediated chemoprotection against chemical hepatocarcinogenesis in rats: haematological and histological characteristics. Eur. J. Cancer Prev. 1997, 6:58-70.
55. Bishayee A., Banik S., Mandal A., Marimuthu P., Chatterjee M. Vanadium-mediated suppression of diethylnitrosamine-induced chromosomal aberrations in rat hepatocytes and its correlation with induction of hepatic glutathione and glutathione S-transferase. Int. J. Oncol. 1997, 10:413-423.
56. Chatterjee M., Bishayee A. Vanadium - a new tool for cancer prevention. Vanadium in the Environment. Part 2: Health Effects 1998, 347-390. John Wiley and Sons, Inc., New York. J.O. Nriagu (Ed.).
57. Bishayee A., Roy S., Chatterjee M. Characterization of selective induction and alteration of xenobiotic biotransforming enzymes by vanadium during diethylnitrosamine-induced chemical rat liver carcinogenesis. Oncol. Res. 1999, 11:41-53.
58. Chakraborty A., Selvaraj S. Differential modulation of xenobiotic metabolizing enzymes by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in Sprague-Dawley rats. Neoplasma 2000, 47:81-89.
59. Chakraborty T., Chatterjee A., Rana A., Dhachinamoorthi D., Kumar A.P., Chatterjee M. Carcinogen-induced early molecular events and its implication in the initiation of chemical hepatocarcinogenesis in rats: chemopreventive role of vanadium on this process. Biochim. Biophys. Acta 2007, 1772:48-59.
60. Chakraborty T., Pandey N., Chatterjee A., Ghosh B., Rana B., Chatterjee M. Molecular basis of anticlastogenic potential of vanadium in vivo during the early stages of diethylnitrosamine-induced hepatocarcinogenesis in rats. Mutat. Res. 2006, 609:117-128.
61. Chakraborty T., Chatterjee A., Dhachinamoorthi D., Srivastawa S., Panayappan L., Chatterjee M. Vanadium limits the expression of proliferating cell nuclear antigen and inhibits early DNA damage during diethylnitrosamine-induced hepatocellular preneoplasia in rats. Environ. Mol. Mutagen. 2006, 47:603-615.
62. Chakraborty T., Chatterjee A., Saralaya M.G., Chatterjee M. Chemopreventive effect of vanadium in a rodent model of chemical hepatocarcinogenesis: reflections in oxidative DNA damage, energy-dispersive X-ray fluorescence profile and metallothionein expression. J. Biol. Inorg. Chem. 2006, 11:855-866.
63. Chakraborty T., Swamy A.H., Chatterjee A., Rana B., Shyamsundar A., Chatterjee M. Molecular basis of vanadium-mediated inhibition of hepatocellular preneoplasia during experimental hepatocarcinogenesis in rats. J. Cell. Biochem. 2007, 101:244-258.
64. Chakraborty T., Ghosh S., Datta S., Chakraborty P., Chatterjee M. Vanadium suppresses sister-chromatid exchange and DNA-protein crosslink formation and restores antioxidant status and hepatocellular architecture during 2-acetylaminofluorene-induced experimental rat hepatocarcinogenesis. J. Exp. Ther. Oncol. 2003, 3:346-362.
65. Chakraborty T., Samanta S., Ghosh B., Thirumoorthy N., Chatterjee M. Vanadium induces apoptosis and modulates the expressions of metallothionein, Ki-67 nuclear antigen, and p53 during 2-acetylaminofluorene-induced rat liver preneoplasia. J. Cell. Biochem. 2005, 94:744-762.
66. Chakraborty T., Chatterjee A., Saralaya M.G., Dhachinamoorthi D., Chatterjee M. Vanadium inhibits the development of 2-acetylaminofluorene-induced premalignant phenotype in a two-stage chemical rat hepatocarcinogenesis model. Life Sci. 2006, 78:2839-2851.
67. Chakraborty T., Chatterjee A., Rana A., Rana B., Palanisamy A., Madhappan R., Chatterjee M. Suppression of early stages of neoplastic transformation in a two-stage chemical hepatocarcinogenesis model: supplementation of vanadium, a dietary micronutrient limits, cell proliferation and inhibits the formations of 8-hydroxy-2'-deoxyguanosines and DNA strand-breaks in the liver of Sprague-Dawley rats. Nutr. Cancer 2007, 59:228-247.
68. 3 inhibit placental glutathione S-transferase positive foci in rat liver carcinogenesis. Life Sci. 2000, 68:217-231.
69. 3 inhibit diethylnitrosamine-induced rat liver carcinogenesis. Chem. -Biol. Interact. 2000, 128:1-18.
70. 3. Biochim. Biophys. Acta 2000, 1502:273-282.
71. Chattopadhyay M.B., Kumar C.B.M., Kanna P.S., Ray R.S., Roy S., Chatterjee M. Combined supplementation of vanadium and beta-carotene suppresses placental glutathione S-transferase-positive foci and enhances antioxidant functions during the inhibition of diethylnitrosamine-induced rat liver carcinogenesis. J. Gastroenterol. Hepatol. 2004, 19:683-693.
72. Chattopadhyay M.B., Mukherjee S., Kulkarni I., Vijayan V., Doloi M., Kanjilal N.B., Chatterjee M. Proton-induced X-ray emission (PIXE) analysis and DNA-chain break study in rat hepatocarcinogenesis: a possible chemopreventive role by combined supplementation of vanadium and beta-carotene. Cancer Cell Int. 2005, 5:16.
73. Djordjevic C., Wampler G.L. Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J. Inorg. Biochem. 1985, 25:51-55.
74. Sardar S., Mondal A., Chatterjee M. Protective role of vanadium in the survival of hosts during the growth of a transplantable murine lymphoma and its profound effects on the rates and patterns of biotransformation. Neoplasma 1993, 40:27-30.
75. Chakraborty A., Chatterjee M. Enhanced erythropoietin and suppression of γ-glutamyl transpeptidase (GGT) activity in murine lymphoma following administration of vanadium. Neoplasma 1994, 41:291-296.
76. Chakraborty A., Ghosh R., Roy K., Ghosh S., Chowdhury P., Chatterjee M. Vanadium: a modifier of drug-metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. Oncology 1995, 52:310-314.
77. Evangelou A., Karkabounas S., Kalpouzos G., Malamas M., Liasko R., Stefanou D., Vlahos A.T., Kabanos T.A. Comparison of the therapeutic effects of two vanadium complexes administered at low dose on benzo[a]pyrene-induced malignant tumors in rats. Cancer Lett. 1997, 119:221-225.
78. Liasko R., Kabanos T.A., Karkabounas S., Malamas M., Tasiopoulos A.J., Stefanou D., Collery P., Evangelou A. Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo(α)pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res. 1998, 18:3609-3613.
79. F Cruz T., Morgan A., Min W. In vitro and in vivo antineoplastic effects of orthovanadate. Mol. Cell. Biochem. 1995, 153:161-166.
80. Jackson J.K., Min W., Cruz T.F., Cindric S., Arsenault L., Von Hoff D.D., Dragan D., Hunter W.L., Burt H.M. A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice. Br. J. Cancer 1997, 75:1014-1020.
81. Rizk S.L., Sky-Peck H. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984, 44:5390-5394.
82. 48V])vanadyl-pheophorbide in tumor as new tumor imaging agent. Int. J. Rad. Appl. Instrum. B 1989, 16:783-789.
83. 6 Na as a tumor-imaging agent in tumor-bearing mice. Int. J. Rad. Appl. Instrum. B 1990, 17:775-780.
84. Warburg O. On the origin of cancer cells. Science 1956, 123:309-314.
85. Mustafi D., Peng B., Foxley S., Makinen M.W., Karczmar G.S., Zamora M., Ejnik J., Martin H. New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer. J. Biol. Inorg. Chem. 2009, 8:1187-1197.
86. Domingo J.L., Sanchez D.J., Gomez M., Llobet J.M., Corbella J. Oral vanadate and Tiron in treatment of diabetes mellitus in rats: improvement of glucose homeostasis and negative side-effects. Vet. Hum. Toxicol. 1993, 35:495-500.
87. Bolkent S., Bolkent S., Yanardag R., Tunali S. Protective effect of vanadyl sulfate on the pancreas of streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 2005, 70:103-109.
88. Yanardag R., Tunali S. Vanadyl sulfate administration protects the streptozotocin-induced oxidative damage to brain tissue in rats. Mol. Cell. Biochem. 2006, 286:153-159.
89. Poucheret P., Verma S., Grynpas M.D., McNeill J.H. Vanadium and diabetes. Mol. Cell. Biochem. 1998, 188:73-80.
90. National Research Council of Canada, Effects of vanadium in the Canadian environment, Report No. 18132, NRCC, Ottawa, 1980.
91. Hirano S., Suzuki K.T. Exposure metabolism and toxicity for rare earths and related compounds. Environ. Health Perspect. 1996, 104:85-95.
92. Proescher F., Seil H.A., Stillians A.W. A contribution to the action of vanadium with particular reference to syphilis. Am. J. Syph. 1917, 1:347-405.
93. Kent N.L., McCance R.A. The absorption and excretion of 'minor' elements by man: silver, gold, lithium, boron, and vanadium. Biochem. J. 1941, 35:837-844.
94. Alimonti A., Petrucci F., Krachler M., Bocca B., Caroll S. Reference values for chromium, nickel and vanadium in urine of youngsters from the urban area of Rome. J. Environ. Monit. 2000, 2:351-354.
95. Somerville J., Davies B. Effect of vanadium on serum cholesterol. Am. Heart J. 1962, 64:54-56.
96. Dimond E.G., Caravace J., Benchimol A. Vanadium, excretion, toxicity, lipid effect in man. Am. J. Clin. Nutr. 1963, 12:49-53.
97. Goldfine A.B., Simonson D.C., Folli F., Patti M.E., Kahn C.R. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 1995, 80:3311-3320.
98. Halberstam M., Cohen N., Shlimovich P., Rossetti L., Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes 1996, 45:659-666.
99. Cohen N., Halberstam M., Shlimovich P., Chang C.J., Shamoon H., Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1995, 95:2501-2509.
100. Boden G., Chen X., Ruiz J., van Rossum G.D., Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism 1996, 45:1130-1135.
101. Fawcett J.P., Farquhar S.J., Thou T., Shand B.I. Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol. Toxicol. 1997, 80:202-206.
102. Goldfine A.B., Patti M.E., Zuberi L., Goldstein B.J., LeBlanc R., Landaker E.J., Jiang Z.Y., Willsky G.R., Kahn C.R. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism 2000, 49:400-410.
103. Cusi K., Cukier S., DeFronzo A., Torres M., Puchulu F.M., Pereira Redondo J.C. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 2001, 86:1410-1417.
104. Jentjens R.L., Jeukendrup A.E. Effect of acute and short-term administration of vanadyl sulphate on insulin sensitivity in healthy active humans. Int. J. Sport Nutr. Exerc. Metab. 2002, 12:470-479.
105. Heinemann G., Fichtl B., Vogt W. Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution. Br. J. Clin. Pharmacol. 2003, 55:241-245.
106. Thompson K.H., Orvig C. Vanadium in diabetes: 100years from phase 0 to phase I. J. Inorg. Biochem. 2006, 100:1925-1935.
107. Etcheverry S.B., Ferrer E.G., Naso L., Rivadeneira J., Salinas V., Williams P.A. Antioxidant effects of the VO(IV) hesperidin complex and its role in cancer chemoprevention. J. Biol. Inorg. Chem. 2008, 13:435-447.